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Objective: To review the use of animal models of osteoarthritis (OA) with regard to their utility for
investigation of the mechanisms and regulation of structural pathology and pain.
Methods: PubMed searches were conducted using separate clusters of terms to retrieve articles on
(i) models of structural joint damage in genetically-modiﬁed (GM) mice, and (ii) models of OA joint pain.
The papers were reviewed to investigate whether there was evidence that the research outcome was
dependent on the model used.
Results: Out of a total of 109 separate GMmice strains identiﬁed in which an effect on OAwas reported, 15
had been studied using more than one arthritis model. In 10/15 the same effect of the GM on arthritis
was reported in at least two different models. In 5/15 the effect of the GM on arthritis structural
pathology was different, and sometimes opposite, when comparing two or more induction methods.
A total of 112 publications were retrieved in which pain/disability was examined in a model suggested to
represent OA. The induction methods used most commonly to study “OA pain” were distinct from those
most often used to investigate the pathophysiology and regulation of structural joint damage. Four
papers directly comparing pain mechanisms in different models were identiﬁed, with 3/4 describing
differences in nociceptive pathways.
Conclusions: The available data indicates that the molecular mechanisms of both joint structural damage
and pain may be distinct in animal models of OA induced or initiated by different means. This suggests
the need to continue using multiple OA animal models but that the subsequent interpretation of the data
and its extrapolation to the human condition must be more precise.
 2012 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Animal models and the ARRIVE guidelines
Animal models are extraordinarily powerful research tools for
studying the pathogenesis and potential therapeutic intervention
of many different diseases. They provide a key step not only in the
knowledge development pathway but also contribute signiﬁcantly
to the “translatability” of drug discovery projects toward clinical
realization1e3. It is scientiﬁcally incumbent upon us as researchers
to do everything possible to make certain that our experiments are
well designed, controlled, powered, analyzed and reported. In the
case of research involving animal models, this is true not only from
the perspective of good scientiﬁc practice but also to fulﬁll ourC.B. Little, Raymond Purves
titute of Medical Research,
ydney at Royal North Shore
ards, NSW 2065, Australia.
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s Research Society International. Presponsibility for the appropriate and ethical use of animals
i.e., implementing the “3Rs” (Reduce the number of animals used,
Reﬁne the procedures and protocols to minimize suffering and
maximize the value of the outcomes, and where possible Replace
animal studies with an alternative approach). A critical component
of “reduction and reﬁnement” in any animal experiment is
ensuring that such studies are appropriately planned, evaluated,
and reported. Poor reporting is as problematic as poor experi-
mental design in diminishing the value and validity of any scientiﬁc
research. Recent reviews have highlighted the deﬁciencies in
reporting in many studies using animal models for a variety of
diseases, and those for osteoarthritis (OA) are no exception4e6.
In this edition of Osteoarthritis and Cartilage, the ARRIVE
guidelines4 have been re-published. These guidelines were devel-
oped to provide a comprehensive checklist for authors to follow to
ensure appropriate reporting of any research using animals, and
their use is now a recommendation for submission of such manu-
scripts to OA&C. While broadly applicable to all animal-based
studies, the importance of the ARRIVE guidelines as theyublished by Elsevier Ltd. All rights reserved.
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the accompanying editorial (Ref OAC6571 e to be inserted once
ﬁnalized). In the long term, use of these guidelines will promote
more consistent publication of OA animal studies, ultimately
enabling better comparisons between laboratories and systematic
reviews of the literature. Although the emphasis is on “reporting”,
the ARRIVE and other guidelines5,6, along with Dr Percie du Sert’s
editorial, should be consulted BEFORE embarking on a study using
animals, not just afterward while writing the manuscript. Consid-
ering the checklist items while designing the study will enable
researchers to control for factors that can signiﬁcantly alter the
experimental outcomes, and hamper or even invalidate the inter-
pretation of the data.
OA e one disease or many?
One of the many items covered in the ARRIVE guidelines is
justiﬁcation for choosing, and recognizing/discussing the limita-
tions of the particular animal model used (guideline items 3b and
18b). The best designed, controlled, and reported study will be
scientiﬁcally and ethically ﬂawed if the model used does not in fact
“do what it says on the label” and model the disease in question. In
the case of OA animal models this issue can be particularly vexing.
The variety of OA animal models available has previously been
reviewed7e9, and revealed over 20 different induction methods
(e.g., spontaneous, surgical, chemical, etc.) in 10 different species of
varying strain, age, and gender. Clearly interpreting the data arising
from such a diverse experimental background is a daunting task,
and will not ultimately be amenable to meta-analysis no matter
how consistently and well reported. This would not be the case if
one or a much more limited number of OA animal models were
routinely used across all laboratories. To date no ideal OA animal
model has been described, and the question might be “whether
a single (or even limited number of) superior OA animal model(s)
exists, and indeed whether it should?” OA in humans and other
species may not be a single disease but rather a syndrome with
a characteristic pattern of clinical signs (pain, disability) and
pathological changes in joint tissues (typically including cartilage
erosion, thickened subchondral bone of reduced mineral density,
excessive marginal new bone (osteophytes), synovitis and joint
capsule thickening/ﬁbrosis). There is an emerging idea that the
syndrome of OA is actually a collection of different disease sub-
types, stratiﬁed amongst other things by the degree of pathology
in different tissues, the rate of progression, the severity of symp-
toms, the initiating cause(s), the gender of the patient and even the
particular joint affected, but all with a similar ﬁnal clinico-
pathological endpoint10.
Stratiﬁcation such as described above, is only important if it has
clinical relevance, being predicated on the hypothesis that the
molecular pathogenesis of OA joint damage and its clinical symp-
tomology may be different for each sub-type. This then would lead
to the premise that the therapeutic approach for disease modiﬁ-
cation and/or symptom management may be “OA sub-type
speciﬁc”, and in part could explain the failure rate of human ther-
apeutic clinical trails for OA that have generally approached the
disease as a single entity. The alternative hypothesis would be that,
at least at some therapeutically applicable stage of disease prior to
irrevocable damage, common structural pathology and/or pain
pathways come into play irrespective of disease sub-type. This then
would suggest that a limited number of therapies would be broadly
applicable to structural and clinical disease modiﬁcation in all/most
OA patients. While vital to consider for management of the patient,
these two paradigms also have very important implications with
respect to the current discussion of appropriate OA animal models.
The disease stratiﬁcation concept supports the need to use many/multiple OA sub-typemodels with subsequent cautious and precise
interpretation of the data, and translation to speciﬁc sub-
populations of human OA patients. This might perhaps also argue
the need for including a preﬁx to deﬁne the particular “OA” being
studied, such as early-, late-, post-traumatic-, age-associated-,
inﬂammatory-, cartilage-erosive-, osteophytic-, etc. On the other
hand, the second paradigm would suggest we either strive for
a reduced number or even single animal model of OA to facilitate
meta-analysis, or equally that it does not matter howmany models
exist and are used, as all would provide information that is globally
applicable. Interestingly, both arguments are used in the OA
research community and literature when it comes to either
defending use of a particular animal model or explaining the lack of
efﬁcacy and translation of a given therapeutic from animals to
humans. When considering the ARRIVE guidelines and justifying
the choice of OA animal model used in an experiment, what
arguments can be made for either of the above approaches?
Genetically-modiﬁed (GM) mice and models for studying OA
structural change
As noted earlier, OA models have been induced by many
methods in a variety of animal species, and the pros and cons of
these have previously been reviewed7e9. It is clear that a huge
amount of valuable information on OA pathogenesis and treatment
has been gained from the different models and species. For the
purposes of the current discussionwe have focused on different OA
induction methods in mice, not because this is necessarily the best
species, indeed there are some signiﬁcant disadvantages with the
mouse9. Ratherwe have restricted this analysis tomice because this
species offers the potential to use GM animals, an approach that has
had and continues to have, an enormous impact on our under-
standing of the molecular mechanisms of OA initiation and
progression. We previously reviewed the literature on the use of
GM mice in OA research to investigate whether cartilage was
a suitable therapeutic target to treat global joint pathology11. While
the particular OAmodel/inductionmethod used in the variousmice
was noted in this previous study, they were all considered equally.
Thus in one strain the reported effect may have been in sponta-
neous “age-associated-OA”, while in another it was instability
induced by intra-articular collagenase injection, and in a third
“post-traumatic-OA” following a particular surgical strategy to alter
joint biomechanics. In the light of the present discussion, we
searched PubMed using the same terms as previously (“mouse/
mice/murine” and “OA”), and determined if there was any data
comparing the outcome of a given GM using different models that
might mimic different OA sub-types. A total of 953 papers were
retrieved (November 22, 2011), which on further review yielded
reports on 109 separate GM mice in which an effect on OA was
reported. In only 15 of these 109 GM strains of mice was the effect
on more than one arthritis model reported. In 10 of the GM mice
the same outcome (i.e. signiﬁcantly increased or decreased carti-
lage erosion) was reported in at least two different models, most
commonly surgically-induced post-traumatic- and spontaneous
age-associated-OA (Table I). The ﬁndings in Table I support the idea
of a common molecular pathology irrespective of the initiating
cause of OA. Interestingly however, there were ﬁve GM mouse
strains in which different, indeed sometimes completely opposite
effects were reported depending on the model used (Table II). The
comparison of OA models were not always done in the one labo-
ratory or described in the one paper, which could contribute to
differences observed. However, direct comparison of at least two
models was reported either in the one paper or by the one research
group, for Spp1/, Frzb/, Il6/ and S100a9/. Divergent effects
of the same GM on different models of OA (e.g., Il6/ increases
Table I
GM mice in which the same effect on OA-like articular cartilage (AC) damage was reported irrespective of the model. Where indicated changes in other joint tissues such as
subchondral bone (SC bone), osteophytes or synovium/joint capsule were also described
Gene/mutation Notes References
Matrix proteins
Tnc/ Increased aaOA AC damage
Increased ptOA (ACLT/MCLT) AC damage
[34]
Matrix degrading enzymes, enzyme inhibitors & enzyme cleavage sites in substrates
Adamts5Dcat (catalytically inactive) Decreased ptOA (DMM) AC damage
Decreased AIA AC damage (no change in synovial inﬂammation)
[35e40]
Jaffa (aggrecan ADAMTS-site mutation) Decreased ptOA (DMM) AC damage
Decreased AIA AC damage (no change in synovial inﬂammation)
[41]
Sulf1/ Increased aaOA AC damage
Increased ptOA (DMM) AC damage
[42]
Sulf2/ Increased aaOA AC damage
Increased ptOA (DMM) AC damage
[42]
Growth factors, cytokines, effector molecules & their receptors and converting enzymes
Cd59a/ Increased ptOA (DMM and MM) AC damage and synovitis [43]
Increased aaOA AC damage and synovitis [44]
Fgf2/ Increased aaOA AC damage
Increased ptOA (DMM) AC damage
Tnfrsf11bþ/e (osteoprotegerin) Increased aaOA AC damage
Increased ptOA (TMCL/MM) AC damage
[45]
Cellular proteins & transcription factors
Epas1⃞þ/e Decreased ptOA (DMM) AC damage; (no change in subchondral bone)
Decreased ciOA AC damage
[46]
MicroRNA
miR-140/ Increased aaOA AC damage (and PG loss)
Increased ptOA (DMM) AC damage (and PG loss)
[47]
OA MODELS: (1) Spontaneous e age-associated-OA (aaOA); considered age-associated if a progressive worsening of disease with age was reported. (2) Surgical instability e
post-traumatic-OA (ptOA): various methods (DMM ¼ surgical destabilization of the medial meniscus; MM ¼ medial meniscectomy; TMCL/MM ¼ transection of the medial
collateral ligament and partial or complete medial meniscectomy; ACLT/MCLT e anterior cruciate and medial collateral ligament transection; MULTI ¼ transection of anterior
and posterior cruciate ligaments, medial and lateral collateral ligaments and medial and lateral meniscectomy). (3) Collagenase-induced instability e collagenase-induced
arthritis (ciOA). (4) Post-inﬂammatory arthropathies; AIA ¼ antigen-induced arthritis; only included if compared with 1, 2, or 3 above.
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suggest that the stratiﬁcation of at least some sub-types of OA
associated perhaps by age at the time of joint insult, or the degree of
inﬂammation or joint instability, may be important. Furthermore
this data demonstrates that the molecular mechanisms regulating
cartilage damage and therefore its potential treatment, may be
different in sub-types of OA.Table II
GMmice in which a different effect on OA-like AC damage was reported depending on the
bone), osteophytes or synovium/joint capsule were also described
Gene/mutation Notes
Matrix proteins
Spp1/ (osteopontin) No change aaOA AC damage (but increased PG los
Increased ptOA (TMCL/MM) AC damage (but NO c
Matrix degrading enzymes, enzyme inhibitors & enzyme cleavage sites in substrates
Mmp3/ Decreased aaOA AC damage
Decreased ciOA AC damage (and synovial macroph
No change ptOA (DMM) AC damage
Growth factors, cytokines, effector molecules & their receptors and converting enzym
Frzb/ No change aaOA AC damage (or SC-bone but incre
Increased ciOA AC PG loss
Il6/ Increased aaOA AC damage (and SC-bone sclerosis
No change ciOA AC damage
Decreased ptOA (DMM) AC damage
Cellular proteins & transcription factors
S100a9/ No change ptOA (DMM) AC damage
Decreased ciOA AC damage
Decreased AIA AC damage (and synovial inﬂamma
OA MODELS: (1) Spontaneous e age-associated-OA (aaOA); considered age-associated if
post-traumatic-OA (ptOA): various methods (DMM ¼ surgical destabilization of the med
collateral ligament and partial or complete medial meniscectomy; ACLT/MCLT e anterior
and posterior cruciate ligaments, medial and lateral collateral ligaments and medial and
arthritis (ciOA). (4) Post-inﬂammatory arthropathies; AIA ¼ antigen-induced arthritis; oModels for studying OA symptomology
The key clinical feature of OA is joint pain and disability, and the
prevailing paradigm is that OA becomes a clinical syndrome when
there is sufﬁcient joint damage to cause pain and impairment of
function. However, the relationship between pathology in different
joint tissues and existing, incident and progressive OA pain inmodel. Where indicated changes in other joint tissues such as subchondral bone (SC
References
s, SC-bone density, decreased chondrocytes)
hange PG loss, decreased chondrocytes)
[48]
ages)
[49]
[50]
es
ased diaphyseal BMD) [51]
but decreased joint BMD; no change AC PG; male only) [52]
[53]
tion)
[54]
[55]
a progressive worsening of disease with age was reported. (2) Surgical instability e
ial meniscus; MM ¼ medial meniscectomy; TMCL/MM ¼ transection of the medial
cruciate and medial collateral ligament transection; MULTI ¼ transection of anterior
lateral meniscectomy). (3) Collagenase-induced instability e collagenase-induced
nly included if compared with 1, 2, or 3 above.
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ﬂicting data on the source and regulation of OA pain may be due to
peripheral and central sensitization or adaptation/tolerance, and
changes in the molecular mechanisms and tissues contributing to
pain at different stages of disease. The complex temporal and tissue
interactions mean that pre-clinical study of the causes as well as
local and systemic regulation of pain in OA relies almost exclusively
on in vivo studies. Despite this, the questions surrounding the most
appropriate and valid animal models for OA pain study are as
unclear as those described for investigation of joint tissue
destruction pathways. The data in GM mice presented above,
supports the concept of distinct sub-types of OA disease and
therefore OA model-stratiﬁcation for at least some aspects of joint
structural damage. Whether the same is true for studying the
mechanisms of OA pain has not been established.
We undertook a literature search in PubMed using the key words/
phrases “animal model/models” and “OA” and “pain” (November 25,
2011). This search retrieved 209 publications, and a review of these
papers revealed 112 in which some aspect of pain/disability was
examined in a model purported to represent OA. In these papers 18
different arthritis induction methods were used and a total of nine
different species were examined (Table III). A variety of outcome
measures of “OA pain” were used including changes in: spontaneous
locomotor (and other) activities, gait, limb loading, locomotor endur-
ance, grip strength, ipsi- and contra-lateral mechanical allodynia and
mechanical and thermal hyperalgesia, and spontaneous and evoked
joint afferentnerveactivity. In somestudiesonlya singlepainoutcome
was evaluatedwhile in others up to ﬁve different painmeasures were
used. In many of these studies changes in pain outcomes were
measured longitudinally and also before and after administration of
various analgesics and/or inhibitors of endogenous opioids.Table III
Animal models used to study the pain of OA
Animal Model Species Outcome measures
Spontaneous
Age associated Guinea pig Mechanosensitivity (EP)
Obesity Mouse Grip strength meter, motor coordinatio
Intra-articular injection
MIA Rat, Mouse Grip strength meter, thermal hyperalge
mechanical allodynia (VF), mechanosen
Na Urate Cat, Parrot Weight distribution, subjective pain sc
AIA Mouse, Rat HL weight distribution (incapacitance),
2 mechanical hyperalgesia (DPA), rang
Adjuvant Rabbit, Rat HL weight distribution; Mechanical hyp
Carrageenan/Kaolin Mouse, Guinea pig, Rat Thermal hyperalgesia (Hargreaves & ho
Instability (surgical)
ACLT Rat, Dog, Rabbit Gait analysis
MCLT Rat HL weight distribution (incapacitance)
MMT, MM (unilateral) Rat, Sheep HL weight distribution (incapacitance),
MM (bilateral) Sheep Ground reaction force
MM (partial) Rabbit, Rat, Mouse HL weight distribution (incapacitance),
DMM Mouse HL weight distribution (incapacitance),
IA OC fragment Horse Clinical observation of lameness
ACLT & partial MM Rat, Guinea pig Gait analysis (CatWalk), mechanical all
ACLT/MMT/MCLT Rat Rotarod
MCLT & MMT Rat Mechanical allodynia (VF), thermal hyp
(incapacitance), mechanical hyperalges
Instabilty (enzymatic)
Collagenase Mouse Visual gait analysis (treadmill), joint te
Genetic modiﬁcation
IL1B over expression Rat Thermal hyperalgesia, mechanical allod
Col9a1 (/) Mouse Motor coordination (rotarod), gait anal
(hotplate, tail ﬂick), grip strength
Key: HL¼ hind limb, VF¼ Von frey ﬁlaments, EP¼ electrophysiological recordings from kn
motion analysis, VRA ¼ videoradiographic analysis, DPA ¼ dynamic plantar aesthesiome
and analysis system, MIA ¼monoiodoacetate induced arthritis, ACLT ¼ anterior cruciate
meniscal transection, MM ¼ medial meniscectomy, DMM ¼ destabilization of the mediaIt is noteworthy that the animal models usedmost commonly to
study “OA pain” were distinct from those most often used to
investigate the pathophysiology and regulation of structural joint
damage (e.g., Tables I and II). In the latter it is generally accepted
that the model should reﬂect both the global joint tissue pathology
seen in human OA, AND that the induction method has some
physiological relevance to naturally-occurring initiating events or
risk factors such as aging, obesity and joint injury7e9. In the reports
of OA pain research in contrast, there was an over representation of
studies using intra-articular injection of monoiodoacetate (MIA),
with 50% of all studies using this model. MIA inhibits the glycolytic
pathway causing rapid widespread chondrocyte death, extensive
neovascularization and invasion of the deep cartilage layers, sub-
chondral bone necrosis and collapse, as well as profound and
prolonged inﬂammation21,22. The initiating event and many of the
pathology changes are not typical of OA, and recent studies have
highlighted the differences in the cartilage transcriptome between
MIA-induced arthritis and human OA23. A further 17% of the papers
use other induction methods that also induce joint pathology that
would not be widely accepted as typical of OA, largely inducing an
acute inﬂammatory arthropathy (e.g., intra-articular injection of
carrageenan/kaolin, Freund’s adjuvant or sodium urate). Only
a minority of the publications retrieved used models generally
accepted to broadly mimic human OA: 25% used surgically-induced
instability models, one paper evaluated pain in the collagenase-
induced instability model, three papers examined age-associated-
OA and only one obesity-induced OA.
It appears there is a signiﬁcant disconnect in the animal models
used to study structural versus symptomatic aspects of OA, indeed
separate models are sometimes used in the one publication24.
The question is whether this separation of animal models to studyn (rotarod), gait analysis, spontaneous locomotor activity
sia, mechanical hyperalgesia, HL weight distribution (incapacitance),
sitivity (EP), gait analysis (CatWalk)
ores
mechanical allodynia (VF), 1 mechanical hyperalgesia (PAM),
e of motion (VRA), gait analysis
eralgesia (VF)
tplate)
mechanical allodynia (VF)
tactile allodynia (VF)
mechanical allodynia (VF), thermal hyperalgesia, locomotor activity (LABORAS)
odynia (VF)
eralgesia (Hargreaves apparatus), HL weight distribution
ia (paw pressure device)
nderness (palpometer)
ynia (VF), gait analysis (Catwalk), foot printing, HL weight distribution, treadmill
ysis, mechanical allodynia (VF), thermal hyperalgesia
ee joint afferents, PAM¼ pressure applicationmeasurement device, ROM¼ range of
ter (automated VF), LABORAS ¼ laboratory animal behavior observation registration
ligament transection, MCLT ¼medial collateral ligament transection, MMT ¼medial
l meniscus, IA OC fragment ¼ intra-articular osteochondral fragment.
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whether the mechanisms and importantly pharmacological control
of pain are similar in all models of chronic joint disease, or whether
the distinct temporal pattern of structural damage in early and
progressive OA drives particular pain mechanisms. Recent studies
of post-traumatic-OA in mice using multiple outcome measures
suggest that in this sub-type of OA there are quite distinct phases of
inﬂammatory and non-inﬂammatory pain, and accompanying
changes in dorsal root ganglia (DRG) gene expression, sensitization
and endogenous opioid driven adaptation25e27. Comparison of
different OA models in GM mice suggested there may be distinct
molecular mechanisms regulating cartilage erosion dependent on
the sub-type of disease (Table II). We found very few studies in
which pain outcomes in different arthritis models were directly
compared28e31. All four of these studies were done in rats, two
comparing MIA-induced arthritis with a post-traumatic surgical
model, and two MIA versus intra-articular Freund’s adjuvant
injection. Differences were noted between MIA and adjuvant in
terms of response to speciﬁc analgesic therapies (TRPA1 receptor
antagonist, diclofenac). When comparing MIA- and surgically-
induced arthritis, one study reported similar changes in DRG gene
expression although comparative pain outcomes were not re-
ported29, while the other found differences between the two
models for alteration in gait, mechanical allodynia, and concen-
tration of substance P in the DRG28. This small cohort of compar-
ative studies tends to suggest there are distinct nociceptive
mechanisms in different models of joint disease, and argues for use
of more appropriate models in OA pain research.
Conclusions and a call for consensus
Attempts are being made to standardize pre-clinical OA studies
particularly those that use animal models. OARSI recently pub-
lished guidelines for histological evaluation of OA models in
a variety of species32, which will hopefully enhance cross-
publication and cross-laboratory comparisons. The re-publication
of the ARRIVE guidelines in this journal is a further step toward
the same goals, by promoting better uniformity in the factors
controlled and reported in OA animal model research. In the
present review we have tried to address the question of whether
more widespread use of a reduced number of speciﬁc OA animal
models might also be possible and facilitate research outcomes. The
available data suggests that the molecular mechanism of both joint
structural damage and pain may well be distinct in OA induced or
initiated by different means. This then argues the need to continue
using and studying multiple OA animal models rather than
pursuing a single “ideal” but also that the subsequent interpreta-
tion of the data and its extrapolation to the human condition must
bemore precise. As noted earlier, it may be helpful tomore formally
classify the possible sub-type of OA that is being modeled. In some
cases, particular arthritis models should perhaps not use the term
“OA” at all if this cannot be justiﬁed based on pathophysiological
relevance to a naturally-occurring human condition. We would
suggest based on available evidence, that there should be better
convergence of the models used to investigate structural OA
pathology and those for pain. That a given arthritis model induces
more robust and easily studied pain outcomes should not be an
argument for its continued use and then extrapolation of the
ﬁndings to “OA pain”, rather it is a reason to improve the methods
for measuring pain so that these can be reliably used in a more
physiologically relevant OA model.
In spite of the above recommendations there remains a vast
array of animal models of OA to choose from, with selection of one
over another being driven more by convenience or past experience
than merit. Even within a particular OA sub-type e.g., surgically-induced post-traumatic-OA, there may be multiple available
models with little data to indicate whether or not they are directly
comparable for pain and structural disease outcomes. This has
obvious implications for advancing scientiﬁc understanding of OA
and deﬁning new therapeutics but also the relative “strength” of
the animal model data feeds directly into metrics that may be used
by industry or possibly funding bodies in making decisions to
continue particular research or drug development programs1e3.
The Canadian Arthritis Network33 and Arthritis Research UK (in
press) have held workshops on pre-clinical OA animal models
providing very useful discussion on their merits and limitations. In
the drive for better standardization and research outcomes, we
suggest there is now a clear need for guidelines on OA animal
models, similar to those that have been developed for histopa-
thology and reporting/publication. In order to facilitate this, we are
initiating a Delphi process to collect and distil the knowledge from
an international group of experts with the aim to produce
a consensus document on OA animal models. An initial series of
“yes/no” questions on what factors are considered important in an
ideal OA animal model will be developed through a repeated
opinion feed back process. The ﬁnal agreed questions will then be
used to rate all existing OA animal models and the results pub-
lished, hopefully to improve not only standardization but also
research outcomes and translation. Invitations to participate in this
process will be sent in 2012, and those interested in potentially
taking part are invited to contact Dr Chris Little.
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